Clinical trials: α-synucleinopathy
Parkinson Disease
Inhibition of α-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine
Lewy Body Dementia (LBD), is the second most common form of dementia after Alzheimer's Disease. Dementia is defined as a serious loss in cognitive ability due to damages or disease in the brain beyond what is normal aging.
- Trial name
- NCT03858270
- Testing
- Memantine
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Wayne State University
Parkinson Disease (PD)
Testing if PDR-001 Can Safely and Effectively Remove Harmful Brain Protein in Parkinson's Disease
Parkinson's disease (PD) poses a severe threat to human health, and its incidence is rising year by year. Current therapeutic options are limited by significant shortcomings.
- Trial name
- NCT07157345
- Testing
- PDR001
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Ruijin Hospital
Parkinson's Disease (PD), Parkinson's Disease
Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease
This clinical study is being conducted to learn more about a new imaging drug called [18F]MK-0947, which is designed to help doctors see changes in the brain related to Parkinson's disease (PD).
- Conditions
- Parkinson's Disease (PD), Parkinson's Disease, Parkinson's Disease (Disorder)
- Trial name
- NCT07348250
- Testing
- [18F]MK-0947
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Invicro
Parkinson Disease, Parkinsonian Disorders
Usefulness of α-synuclein as a Marker for Early Diagnosis of Parkinson's Disease in Skin Biopsy.
Parkinson's disease (PD) is a degenerative disease that can be difficult to diagnose. The clinicopathological studies had demonstrated a 76% accuracy in the clinical diagnosis of PD.
- Trial name
- NCT01380899
- Testing
- Biopsy of skin
- Where
- Mexico
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Universidad Autonoma de San Luis Potosí
REM Sleep Behavior Disorder
Prodromal Markers in Recurrent Dream Enactment Behaviors Without REM Sleep Without Atonia
REM sleep behavior disorder is a novel and distinct parasomnia characterized by recurrent dream enactment behaviors (DEBs) and REM sleep without atonia (RSWA) during polysomnographic assessment, with a male predominance and…
- Trial name
- NCT05353881
- Testing
- No intervention
- Where
- Hong Kong
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Multiple System Atrophy
A Prospective Exploratory Study of the Safety and Preliminary Efficacy of the α-Syn H21 Monoclonal Antibody in Patients With Multiple System Atrophy
Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by autonomic dysfunction, parkinsonism, and cerebellar ataxia.
- Trial name
- NCT07774585
- Testing
- α-Syn H21 Monoclonal Antibody
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Ruijin Hospital
Parkinson's Disease
Prevent Cognitive Decline in GBA-associated Parkinson's Disease
This is a proof-of-concept trial to investigate the efficacy of prasinezumab to slow or prevent cognitive decline in people with Parkinson's disease carrying a severe mutation in the GBA (glucocerebrosidase) gene.
- Trial name
- PreCoDe (NCT07055087)
- Testing
- Prasinezumab, Sodium Chloride
- Where
- 11 sites in France, Germany and 5 more
- Volunteers
- 120 people
- Sponsor
- University Hospital Tuebingen
Parkinson Disease (PD)
Validation of α-synuclein Modifications in Parkinson's dIsoRder Evolution
Parkinson's disease (PD) presents a complex challenge due to its progressive neurodegenerative nature, affecting various bodily systems.
- Trial name
- VaMPiRE (NCT06941012)
- Testing
- Blood draw for the laboratory assessment
- Where
- 4 sites in Greece, Italy and 2 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Casa di Cura IGEA
Parkinsons Disease (PD), Healthy Elderly Volunteers
MK-0947 PN-002: An Open-label Study to Evaluate Brain α-synuclein Deposition Using Positron Emission Tomography (PET) and [¹⁸F]MK-0947 in Participants With Parkinson's Disease (PD)
This is a single-center, open-label clinical study designed to evaluate alpha-synuclein (ASYN) deposition in the brain of participants with Parkinson's disease (PD), as compared with healthy elderly (HE) participants.
- Trial name
- NCT07880379
- Testing
- [¹⁸F]MK-0947
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- XingImaging, LLC
α-synucleinopathy
A Registered Cohort Study on α-Synucleinopathy
α-Synucleinopathy is a cluster of neurodegenerative disease with motor and non-motor symptom. The data to be collected is intended to help healthcare providers make important medical decisions concerning α-synucleinopathy…
- Trial name
- NCT05527067
- Testing
- Data collection
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Fujian Medical University Union Hospital
Parkinson's Disease, Parkinson's Disease Dementia
Nilotinib in Cognitively Impaired Parkinson Disease Patients 001
This pilot study will test Nilotinib's ability to alter the abnormal protein build up in Parkinson disease and Diffuse Lewey Body Disease patients . Patients will receive Nilotinib at different doses for 6 months.
- Conditions
- Parkinson's Disease, Parkinson's Disease Dementia, Diffuse Lewy Body Disease
- Trial name
- NCT02281474
- Testing
- Nilotinib
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Georgetown University
Alpha Synuclein Pathology, Alpha-Synuclein
Alpha-Synuclein PET/CT in Various α-Syn-Related Disease
To evaluate the potential usefulness of 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various α-Syn-related disease patients.
- Conditions
- Alpha Synuclein Pathology, Alpha-Synuclein, Parkinson Disease
- Trial name
- NCT06949670
- Testing
- 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06
- Where
- 3 sites in China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University
REM Sleep Behavior Disorder
Prodromal Markers of First-degree Relatives of Patients With Psychiatric Disorders Comorbid With RBD
REM sleep behavior disorder (typical or 'idiopathic' RBD, iRBD) is a novel and distinct parasomnia characterized by recurrent dream enactment behaviours and polysomnographic features of loss of normal REM-sleep related muscle…
- Trial name
- NCT03595475
- Where
- 2 sites in Hong Kong
- Volunteers
- 408 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Parkinson's Disease, Multiple System Atrophy
An Observational Study of Parkinson's Disease and Other Synucleinopathies (EASE-PD)
The study is a multi-center, observational study to evaluate the feasibility of α-synuclein-related biomarkers and imaging data in the disease diagnosis and prognosis evaluation in Synucleinopathies and healthy subjects.
- Trial name
- EASE-PD (NCT05638815)
- Where
- 4 sites in China
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- SciNeuro
Sleep Disorder Rem Sleep Behavior, Parkinson's Disease, Lewy Body
Establishing Alpha-synuclein RT-QuIC Assay as a Diagnostic Technique in REM Sleep Behaviour Disorder
We hypothesise that a real-time quaking induced conversion assay for the detection of pathological alpha-synuclein (α -syn RTQuIC) can be used to differentiate between cases of idiopathic REM-sleep behaviour disorder (RBD) and…
- Trial name
- NCT04266457
- Testing
- No Intervention
- Where
- United Kingdom
- Sponsor
- University of Edinburgh
Multiple System Atrophy - Cerebellar Subtype (MSA-C), Multiple System Atrophy - Parkinsonian Subtype (MSA-P)
Targeted Α-synuclein PET Imaging in the Diagnosis of Multiple System Atrophy
The aim of this study was to apply the targeted α-synuclein PET study technique to investigate the pathological load and spatial distribution characteristics of α-syn in MSA patients, and to assess its value as a biomarker for…
- Trial name
- NCT06890377
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Min Zhao,MD
Parkinson's Disease (PD), Multiple System Atrophy (MSA)
[18F]ACI-15916 PET in α-synucleinopathies
The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein α-synuclein [involved in some diseases such as Parkinson's disease, Lewy body dementia and Multiple…
- Conditions
- Parkinson's Disease (PD), Multiple System Atrophy (MSA), Dementia With Lewy Bodies (DLB)
- Trial name
- NCT06891703
- Testing
- [18F]ACI-15916
- Where
- Sweden
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- AC Immune SA
REM Sleep Behavior Disorder, Neurodegeneration
Progression of Prodromal Markers of α-synucleinopathy Neurodegeneration in the FDRs of Patients With RBD
This study is a prospective study with a mean of 5-year follow-up interval, aims to monitor the progression of α-synucleinopathy neurodegeneration by the evolution of prodromal markers and development of clinical disorders in…
- Trial name
- NCT03671772
- Where
- Hong Kong
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Positron-Emission Tomography, Alpha Synuclein Pathology
Study of 18F-0502B PET Imaging Targeting α-synuclein in the Diagnosis of α-synuclein-related Diseases
To explore the diagnostic value of 18F-0502B brain imaging for α-Syn protein-related diseases in patients with PD. To evaluate the imaging range of α-Syn protein density in patients with α-Syn protein-related diseases and to…
- Trial name
- NCT05757804
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Huashan Hospital
Parkinson´s Disease, REM Sleep Behavior Disorder (iRBD)
The Swedish BioFINDER Sleep Study
BioFINDER-Sleep study was established in 2021 and will include patients with early Parkinson´s disease (PD) and persons with iRBD to provide essential insights into the underlying mechanisms of the progressive neurodegenerative…
- Conditions
- Parkinson´s Disease, REM Sleep Behavior Disorder (iRBD), Lewy Body Disease, Synucleinopathy
- Trial name
- NCT07533799
- Testing
- Dopamine transporter PET scan with [18F]FE-PE2I, Magnetic resonance imaging (MRI), [123I] MIBG scintigraphy of the heart
- Where
- Sweden
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital